GT-001
- Generic Name
- GT-001
Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Safety and Tolerability
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Gabather AB
- Target Recruit Count
- 32
- Registration Number
- NCT03817346
- Locations
- 🇫🇮
CRST Oy, Clinical Research Services Turku, Turku, Finland
A Dose Escalating Study to Assess the Safety and Tolerability of GT-001
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Gila Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03490786
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath